PROTAGENIC THERAPEUTICS,INC. (OTCMKTS:PTIX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 25, 2017, the Board of Directors of Protagenic Therapeutics, Inc. (the “Company”) adopted Amended and Restated Bylaws (“New Bylaws”), which became effective immediately upon adoption and amended and restated the Company’s then-existing Bylaws (“Old Bylaws”). The New Bylaws are intended to eliminate inconsistencies between the Company’s Amended and Restated Certificate of Incorporation (the “Certificate”) and the Old Bylaws. The New Bylaws include the following amendments:

Number and Terms of Directors. The Old Bylaws specified that the directors shall hold office in the manner provided by the Certificate. Since the Certificate does not contain a provision dealing with this matter, the New Bylaws provide that the directors, other than those who may be elected by the holders of any series of Preferred Stock, shall be elected at each annual meeting of stockholders, and each director elected shall hold office until the next annual meeting of stockholders or until such director’s successor is duly elected and qualified or until his or her earlier resignation, death or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

Vacancies in the Board. The Old Bylaws provided that vacancies in the Board of Directors were to be filled in the manner set forth in the Certificate. Since the Certificate does not contain a provision dealing with this matter, the New Bylaws provide that, subject to the rights, if any, of the holders of any series of Preferred Stock to elect directors and to fill vacancies in the Board of Directors relating thereto, any and all vacancies in the Board of Directors, however occurring, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director's successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal.

Removal of Directors. The Old Bylaws provided that directors may be removed from office only in the manner provided in the Certificate. Since the Certificate does not contain a provision dealing with this matter, the New Bylaws provide that, subject to the rights, if any, of any series of Preferred Stock to elect directors and to remove any director whom the holders of any such stock have the right to elect, any director (including persons elected by directors to fill vacancies in the Board of Directors) may be removed from office, with or without cause, only by the affirmative vote of the holders of at least a majority in voting power of the shares then entitled to vote at an election of directors.

The foregoing summary is not, nor is it intended to be, a complete or comprehensive summary of all of the changes to the Company's Bylaws, and it is qualified in its entirety by the full text of the Second Amended and Restated Bylaws, a copy of which is being filed as Exhibit 3.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

______________

*Filed herewith.

Protagenic Therapeutics, Inc.new Exhibit
EX-3.1 2 ex3-1.htm EXHIBIT 3.1 ex3-1.htm Exhibit 3.1   FIRST AMENDED AND RESTATED BYLAWS   OF   PROTAGENIC THERAPEUTICS,…
To view the full exhibit click here

About PROTAGENIC THERAPEUTICS,INC. (OTCMKTS:PTIX)

Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.